SecBot SecBot
SC 13G/A ·Filed Nov 6, 2026

CTNM

Contineum Therapeutics, Inc.
NEUTRAL
Impact 3/10
Horizonimmediate Processed10d 17h ago SEC0000904454-26-000591
Passive stake amendment
Actionable Insight • Neutral

J&J's increased passive stake adds to a cluster of recent institutional 13G filings (Fidelity, Squadron Capital, Franklin Templeton) over the past two weeks. Monitor for any conversion to a 13D or further accumulation, though the passive certification suggests no imminent activist intent.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$9.52
T+0 close · Nov 6, 2026 · via day close
Latest settled
+3.57%
T+5 · $9.86
Vs SPY
+0.98%
α at T+5
Next horizon
T+20
in 20d
  1. T+0 · Nov 6 $9.52entry
  2. T+1 · 8d ago +8.19%α +5.83% · $10.30
  3. T+5 · 4d ago +3.57%α +0.98% · $9.86
  4. T+6 · todayOpen
  5. T+20 · in 20d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Johnson & Johnson Innovation-JJDC (a J&J subsidiary) filed an amended Schedule 13G disclosing a 5.6% passive stake in Contineum Therapeutics as of November 3, 2026, up from a prior filing. The stake consists of 1,979,173 shares, and the filing reaffirms passive intent with no control influence.

Key Financial Metrics

Stake
5.6%
Stake Value
$21.8M
Investor
Johnson & Johnson Innovation - JJDC, Inc.

Key Facts

  • Johnson & Johnson Innovation-JJDC disclosed 1,979,173 shares of CTNM common stock, representing 5.6% of shares outstanding.
  • The filing is an amendment to a prior Schedule 13G, indicating an increase from the previously reported stake.
  • The stake is based on 35,353,313 shares outstanding as of October 30, 2026.
  • The filing certifies passive intent under Rule 13d-1(c), with no purpose of changing or influencing control.

Financial Impact

Stake valued at approximately $21.8M based on market cap of $384M and 5.6% ownership.

ownership_percentage

Risk Factors

  • No material risks identified; routine passive stake amendment.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
79% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
SC 13G/A Filing (Primary)0000904454-26-000591
Document: 0000904454-26-000591-index.html0000904454-26-000591
Document: 0000904454-26-000591.txt0000904454-26-000591

US Market Status

Market Closed · Opens in 5h 30m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 6, 2026